Literature DB >> 17192156

Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus.

Kerry L LaPlante1, Michael J Rybak, Muhammad Amjad, Glenn W Kaatz.   

Abstract

STUDY
OBJECTIVE: To differentiate the characteristics of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MRSA isolates on the basis of their susceptibility profiles, induction of clindamycin resistance, and staphylococcal chromosomal cassette (SCC) mec types.
DESIGN: In vitro molecular and susceptibility study of isolates obtained from December 2004-January 2006 as part of a large, ongoing clinical study.
SETTING: Level I trauma center in Detroit, Michigan. BACTERIAL STRAINS: Three hundred eight MRSA isolates randomly collected from patients; 130 were classified as community-associated, and 178 were classified hospital-associated by using definitions from the Centers for Disease Control and Prevention (CDC). INTERVENTION: Minimum inhibitory concentrations were tested on the basis of current guidelines from the Clinical and Laboratory Standards Institute.
MEASUREMENTS AND MAIN RESULTS: All tested MRSA isolates were susceptible to daptomycin, linezolid, and vancomycin. In addition, community-associated MRSA isolates were significantly (all p < or = 0.05) more susceptible to trimethoprim-sulfamethoxazole (99%), clindamycin (96%), and a fluoroquinolone (76%) than hospital-associated MRSA isolates. Inducible resistance to clindamycin was demonstrated in 8.4% of community-associated MRSA isolates versus 50% of hospital-associated MRSA isolates (p < or = 0.001). Of interest, 35% of the MRSA isolates collected from hospitalized patients (> 48 hrs after admission and according to the CDC definition) possessed SCCmec type IV.
CONCLUSION: Overall, inducible clindamycin resistance occurred at significantly higher rates in the hospital-associated MRSA isolates, susceptibility differed significantly between community- and hospital-associated MRSA, and most of the hospital isolates contained SCCmec type IV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192156     DOI: 10.1592/phco.27.1.3

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  12 in total

1.  High prevalence of ST121 in community-associated methicillin-susceptible Staphylococcus aureus lineages responsible for skin and soft tissue infections in Portuguese children.

Authors:  T Conceição; M Aires-de-Sousa; N Pona; M J Brito; C Barradas; R Coelho; T Sardinha; L Sancho; G de Sousa; M do Céu Machado; H de Lencastre
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-03       Impact factor: 3.267

2.  Community-Associated Methicillin-Resistant Staphylococcus aureus in the Pediatric Population.

Authors:  Carrie W Nemerovski; Kristin C Klein
Journal:  J Pediatr Pharmacol Ther       Date:  2008-10

Review 3.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Authors:  Jamese J Hilliard; Jeffrey Fernandez; John Melton; Mark J Macielag; Raul Goldschmidt; Karen Bush; Darren Abbanat
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

5.  In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.

Authors:  Yi Guo; Romela Irene Ramos; John S Cho; Niles P Donegan; Ambrose L Cheung; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

Review 6.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Authors:  Keith A Rodvold; David P Nicolau; Thomas P Lodise; Mohammed Khashab; Gary J Noel; James B Kahn; Mark Gotfried; Sara A Murray; Susan Nicholson; Somvadee Laohavaleeson; Pamela R Tessier; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.

Authors:  Kerry L LaPlante; Steven N Leonard; David R Andes; William A Craig; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

9.  Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.

Authors:  Somvadee Laohavaleeson; Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

10.  Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.

Authors:  Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.